Annular lichenoid dermatitis of youth: report on two adult cases and one child

1173 © 2019 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd. | JDDG | 1610-0379/2019/1711 2 Ständer S, Zeidler C, Augustin M et al. S2k Guidelines for the diagnosis and treatment of chronic pruritus – update – short version. J Dtsch Dermatol Ges 2017; 15(8): 860–72. 3 Roufosse FE, Goldman M, Cogan E, Hypereosinophilic syndromes. Orphanet J Rare Dis 2007; 2: 37. 4 Simon HU, Plötz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999; 341(15): 1112–20. 5 Khoury P, Abiodun AO, Holland-Thomas N et al. Hypereosinophilic syndrome subtype predicts responsiveness to glucocorticoids. J Allergy Clin Immunol Pract 2018; 6(1): 190–5. 6 Nixon J, Newbold P, Mustelin T et al. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation. Pharmacol Ther 2017; 169: 57–77. 7 Hassani M, Koenderman L, Immunological and hematological effects of IL-5(Ralpha)-targeted therapy: An overview. Allergy 2018; 73(10): 1979–88. 8 Rothenberg ME, Klion AD, Roufosse FE et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008; 358(12): 1215–28. 9 Roufosse F, de Lavareille A, Schandené L et al. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol 2010; 126(4): 828–835.e3. 10 Klion AD, Law MA, Noel P et al. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 2004; 103(8): 2939–41. 11 Kuruvilla M, Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab. Ann Allergy Asthma Immunol 2018; 120(6): 670–1.